EP 1317284 A2 20030611 - ANTIBODY AND/OR CHEMOKINE CONSTRUCTS WHICH BIND TO A CHEMOKINE RECEPTOR AND THEIR USE IN IMMUNOLOGICAL DISORDERS
Title (en)
ANTIBODY AND/OR CHEMOKINE CONSTRUCTS WHICH BIND TO A CHEMOKINE RECEPTOR AND THEIR USE IN IMMUNOLOGICAL DISORDERS
Title (de)
ANTIKÖRPER- UND/ODER CHEMOKINKONSTRUKTE DIE AN EINEN CHEMOKINREZEPTOR BINDEN UND DEREN VERWENDUNG IN IMMUNOLOGISCHEN ERKRANKUNGEN
Title (fr)
CONSTRUCTIONS D'ANTICORPS ET/OU DE CHIMIOKINE QUI SE LIE A UN RECEPTEUR CHIMIOKINE ET LEUR UTILISATION CONTRE DES TROUBLES IMMUNOLOGIQUES
Publication
Application
Priority
- EP 01980364 A 20010910
- EP 0110433 W 20010910
- EP 00119694 A 20000908
- US 94800401 A 20010905
Abstract (en)
[origin: WO0220615A2] The present invention relates to the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition for the elimination of cells which are latently infected with a primate immunodeficiency virus. In addition, the present invention provides for the use of an antibody and/or chemokine construct which binds to a chemokine receptor for the preparation of a pharmaceutical composition of the treatment, prevention and/or alleviation of inflammatory renal diseases, inflammatory bowel diseases, multiple sclerosis, skin diseases, diabetes or transplant rejection. Furthermore, the invention relates to antibody constructs and/or chemokine constructs wherein said antibody construct comprises a binding site of chemokine receptor 5 and a binding site for CD3 and wherein said chemokine construct comprises RANTES and a toxin. The invention also describes polynucleotides encoding said antibody- or chemokine constructs, and vectors and hosts comprising said nucleic acid molecules. Additionally, the present invention relates to compositions comprising said antibody constructs, chemokine constructs, polynucleotides, vectors and/or hosts. Preferably said composition is a pharmaceutical composition. Described is also the use of antibody constructs, the chemokine constructs, the polynucleotides, the hosts and/or the vectors of the preparation of a pharmaceutical composition and methods for treating, preventing and/or alleviating an immunological disorder or for eliminating latently infected cells, wherein said cells are infected with a primate immunodeficiency virus, like HIV-1. Furthermore, the invention provides for a kit comprising the compounds of the invention.
IPC 1-7
A61K 39/395; A61K 38/19; A61K 47/48; C12N 15/12; C12N 15/13; C12N 15/62; C12N 15/79; C07K 16/28; C07K 19/00; A61K 31/7088; A61P 17/00; A61P 19/00; A61P 31/18; A61P 37/06
IPC 8 full level
A61K 31/7088 (2006.01); A61K 35/76 (2006.01); A61K 38/00 (2006.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01); A61P 1/00 (2006.01); A61P 3/10 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 17/06 (2006.01); A61K 48/00 (2006.01); A61P 19/00 (2006.01); A61P 19/02 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 31/18 (2006.01); A61P 37/02 (2006.01); A61P 37/06 (2006.01); A61P 37/08 (2006.01); C07K 14/52 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/09 (2006.01); C12N 15/12 (2006.01); C12N 15/13 (2006.01); C12N 15/62 (2006.01); C12N 15/79 (2006.01); C12P 21/02 (2006.01); C12P 21/08 (2006.01); A61K 39/00 (2006.01)
IPC 8 main group level
C07K (2006.01)
CPC (source: EP)
A61P 1/00 (2018.01); A61P 3/10 (2018.01); A61P 13/12 (2018.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01); A61P 19/00 (2018.01); A61P 19/02 (2018.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01); A61P 31/18 (2018.01); A61P 37/02 (2018.01); A61P 37/06 (2018.01); A61P 37/08 (2018.01); C07K 14/523 (2013.01); C07K 16/2809 (2013.01); C07K 16/2866 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/77 (2013.01); C07K 2319/00 (2013.01)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0220615 A2 20020314; WO 0220615 A3 20020725; AU 1222502 A 20020322; CA 2421842 A1 20020314; EP 1317284 A2 20030611; HU P0300942 A2 20030929; JP 2004508036 A 20040318; NO 20031070 D0 20030307; NO 20031070 L 20030506; PL 366062 A1 20050124; RU 2252786 C2 20050527; ZA 200301890 B 20040316
DOCDB simple family (application)
EP 0110433 W 20010910; AU 1222502 A 20010910; CA 2421842 A 20010910; EP 01980364 A 20010910; HU P0300942 A 20010910; JP 2002525234 A 20010910; NO 20031070 A 20030307; PL 36606201 A 20010910; RU 2003108885 A 20010910; ZA 200301890 A 20030307